Neovasc, Inc. (NASDAQ:NVCN) to Present Tiara and Reducer Data at TCT in Washington DC

Specialty medical device company, Neovasc, Inc. (NASDAQ:NVCN), announced that it will make several presentations at the Transcatheter Cardiovascular Therapeutics in Washington, DC.

VANCOUVER, Oct. 26, 2016 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NVCN) (NVC.TO) outlined today its notable presentations at the upcoming annual Transcatheter Cardiovascular Therapeutics (TCT) symposium, the world’s largest educational meeting specializing in interventional cardiovascular medicine in Washington, DC from October 29 to November 2, 2016.

On October 31, Dr. Anson Cheung will be providing an update on the Tiara transcatheter mitral valve clinical program.  Tiara devices are currently being implanted under compassionate use in several geographies, as well as in the TIARA-I Early Feasibility Trial, a multinational, multicenter trial being conducted in the US, Europe and Canada. The trial is assessing the safety and performance of the Tiara mitral valve system and the implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).

Also on October 31, Dr. Gregg Stone will be highlighting Reducer’s clinical results in treating refractory angina.  Reducer, CE-marked in Europe, is a medical device that provides relief of severe angina symptoms by increasing pressure in the coronary sinus, thus redistributing blood flow into the ischemic heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

Original Source

neovasc-graph

Neovasc, Inc. (NASDAQ:NVCN) shares have moved -48.165% on the news thus far today and have traded in the range of $0.476 – 0.660 during the current session. In order to take a look at where the stock might be headed longer term, investors often look to research firms that cover the stock. Sell-side research firms currently have a consensus one-year price target of $2.130 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  The sell-side analysts are projecting earnings per share of $-0.070 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-2.410 per share according to First Call.

Are Shares of Neovasc, Inc. (NASDAQ:NVCN) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where the stock is trading on a technical level, the stock is trading -64.310% away from its 50-day moving average of $1.583.  Based on the most recent available data, the equity is -90.504% off of its 52-week high of $5.950 and +18.697% away from its 52-week low which is $0.476.

Today, the stock opened at $0.630 and the last bid at the time of writing stood at $0.565.  During the session thus far, the equity dipped down to $0.476 and touched $0.660 as the high point.  Neovasc, Inc. (NASDAQ:NVCN) has a market cap of $47.17M and has seen an average daily volume of 463,402 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment